Patent intelligence · US
US 9994585
Transplantation therapies
Transplantation therapies
Patent details — US 9994585
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 12, 2018
- Expiration
- Jun 7, 2038
- Applicant
- Aphios Corporation
- Claims
- 16
- CPC classes
- A61K, A61K31/365, A61K47/14, A61P
Quick answer
US 9994585 (Transplantation therapies) is held by Aphios Corporation. Status: granted. Granted Jun 12, 2018. Expires Jun 7, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Aphios Corporation
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/365, A61K47/14, A61P, A61P37/06
More from Aphios Corporation
Related pharmaceutical patents in our USPTO index.
-
US 11926828
Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
granted -
US 11639359
Bryoid compositions, methods of making and use thereof
granted -
US 11584933
RNA interference in ocular indications
granted -
US 11396654
Neutral nanotransporters
granted -
US 11279934
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
granted -
US 11254940
Inhibition of MAP4K4 through RNAi
granted -
US 11234932
Combination HIV therapeutic
granted -
US 11118178
Reduced size self-delivering RNAI compounds
granted
Frequently asked questions
What is US patent 9994585?
US 9994585 (Transplantation therapies) is held by Aphios Corporation. Status: granted. Granted Jun 12, 2018. Expires Jun 7, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9994585?
Aphios Corporation is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.
When does US 9994585 expire?
Our index shows an expiration date of Jun 7, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.